#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic myeloid leukaemia Corneal neovascularisation Advanced systemic mastocytosis Mantle cell lymphoma refractory Acute graft versus host disease Immune-mediated myasthenia gravis Liposarcoma Small cell lung cancer recurrent Autoimmune demyelinating disease Rhabdoid tumour Myelofibrosis Sickle cell disease PIK3CA related overgrowth spectrum Endometrial adenocarcinoma Anal cancer More trials…

    Learn about Rare Diseases

    Usher’s syndrome – Basic Information Hyperoxaluria – Basic Information Osteosarcoma – Trials in Disease Erdheim-Chester disease – Life with Disease Indolent systemic mastocytosis – Life with Disease Langerhans’ cell histiocytosis – Diagnostics Fabry’s disease – Life with Disease Breast angiosarcoma – Life with Disease Inclusion body myositis Undifferentiated sarcoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gsk4527226 Bromhexine Hydrochloride Bi 765845 Atl001 Bi 1291583 CANNABINOL Albaconazole Vobramitamab Duocarmazine Pseudoephedrine Hydrochloride RNMB2 Lacnotuzumab Trazodone Apadamtase Alfa Cft1946 Furosemide Ph. Eur. L-Lysine Hydrochloride Doconexent Sufentanil Phenazone Nimodipine More therapies…

    Learn about Your Condition

    Skin angiosarcoma Meningorrhagia Chronic sinusitis Chorioretinitis Emphysema Neuropathic arthropathy Osteoarthritis Head and neck cancer Bartonellosis Porphyria non-acute Infantile spasms Hyperparathyroidism secondary Alveolar rhabdomyosarcoma Hysterectomy Langerhans' cell histiocytosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hemic and Lymphatic Diseases

  • Study Comparing Rituximab with Drug Combination for Patients with Newly Diagnosed High-Risk Burkitt Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Burkitt’s lymphoma
    Investigated Drugs:
    • Ifosfamide
    • Cyclophosphamide
    • Doxorubicin
    Belgium The Netherlands

  • Study on Venetoclax, Ibrutinib, and Obinutuzumab for Chronic Lymphocytic Leukemia Patients Not in Complete Remission or with Detectable Bone Marrow Disease

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Ibrutinib
    • Obinutuzumab
    • Venetoclax
    Denmark The Netherlands

  • Study Comparing Rituximab with Ibrutinib to Rituximab with Chemotherapy for Older Patients with Untreated Mantle Cell Lymphoma

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Mantle cell lymphoma
    Investigated Drugs:
    • Ibrutinib
    • Bendamustine Hydrochloride
    • Cyclophosphamide
    Denmark Finland Norway Sweden

  • Study on Copanlisib and Rituximab for Patients with Marginal Zone Lymphoma Needing Treatment After Local Therapy Failure or Relapse

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Extranodal marginal zone B-cell lymphoma (MALT type)
    • Splenic marginal zone lymphoma
    • Nodal marginal zone B-cell lymphoma
    Investigated Drugs:
    • Copanlisib Dihydrochloride
    • Rituximab
    Germany

  • Study on Stopping Nilotinib, Imatinib, and Dasatinib in Patients with Chronic Myeloid Leukemia in Deep Remission

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Dasatinib
    • Imatinib
    • Nilotinib
    Czechia

  • Long-Term Safety and Efficacy Study of Betibeglogene Autotemcel Gene Therapy for Patients with Transfusion-Dependent Beta-Thalassemia

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Thalassaemia beta
    Investigated Drugs:
    • Betibeglogene Autotemcel
    France Germany Greece Italy
Previous Page
1 … 56 57 58 59 60 … 89
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!